|1.||Risteli, Juha: 11 articles (01/2015 - 07/2002)|
|2.||Gottdiener, John S: 6 articles (10/2015 - 02/2010)|
|3.||Ix, Joachim H: 6 articles (10/2015 - 05/2014)|
|4.||Barasch, Eddy: 6 articles (10/2015 - 02/2010)|
|5.||Kizer, Jorge R: 6 articles (10/2015 - 05/2014)|
|6.||Risteli, J: 6 articles (04/2005 - 05/2000)|
|7.||Glazer, Nicole L: 5 articles (10/2015 - 05/2014)|
|8.||Djousse, Luc: 5 articles (10/2015 - 05/2014)|
|9.||Rimm, Eric B: 4 articles (10/2015 - 06/2014)|
|10.||Agarwal, Isha: 4 articles (10/2015 - 06/2014)|
|1.||Liver Cirrhosis (Hepatic Cirrhosis)
01/01/2015 - "Between January 2013 and June 2014, a total of 228 patients with a clinical diagnosis with liver cirrhosis and without malignancy underwent the tests of HA, LN, PIIINP, and CIV levels. "
04/01/2013 - "All the patients in both groups received the measurements of portal vein, 4 indicators of liver fibrosis (P III P, C IV, HA, LN), and 3 indicators of serum enzyme activities (ALT, AST, gamma-GT). "
11/01/2012 - "Compared to a decision tree model, a simple score system using a categorized value based on a combination of platelet count, HA and PIIINP identified patients with liver cirrhosis with a higher clinical usability."
01/01/2011 - "In adults given the diagnostic accuracy of HA, PIIINP, TGF-ß1, their combination may provide a potential useful tool to assess liver fibrosis. "
08/01/2003 - "Serum levels of YKL-40 and PIIINP are elevated in alcoholic patients, related to the presence of liver fibrosis and may provide prognostic information."
|2.||Liver Diseases (Liver Disease)
04/01/2007 - "Calculation of PIIINP/beta-CTx ratio was found to yield an excellent sensitivity (94%) and specificity (98%) in differentiating the alcoholics with liver disease. "
01/01/1995 - "The extent of liver disease was assessed using measurements of serum aminoterminal propeptide (PIIINP) and Child-Pugh grades. "
06/01/1994 - "Role of the measurement of serum procollagen type III N-terminal peptide in the evaluation of liver diseases."
08/01/1999 - "Using receiver operating characteristic analysis, the two PIIINP assays were compared with serum ALT as markers of liver disease in chronic hepatitis C. "
01/01/1997 - "In this study P-III-P and P1 laminin were not usefull discriminators of severe liver damage among asymptomatic alcoholics; their levels were found to rise significantly only when liver disease has become clinically evident."
|3.||Wounds and Injuries (Trauma)
11/15/1991 - "The differential patterns of PMN-E and PIIINP concentration in knee joint effusions may be useful in estimating the period between trauma and first treatment (aspiration of effusion) and should, therefore, be helpful in detecting degenerative lesions, which seem to be characterized by low PMN-E concomitantly with high PIIINP levels."
04/01/2003 - "The increase of PIIINP after thermal trauma indicates a fibrogenic component of wound healing."
07/01/1993 - "Wound fluid PIIINP reflected the formation of granulation tissue (r = 0.52, p < 0.05), whereas serum PIIINP remained unchanged despite normal formation of granulation tissue. "
07/01/1993 - "In untreated rats, serum PIIINP and wound fluid PIIINP were related to formation of granulation tissue (serum: r = 0.58, p < 0.05; wound fluid: r = 0.56, p < 0.05). "
07/01/1993 - "Because the relative response of PIIINP to abdominal operation was similar in both groups, the PIIINP response to surgical trauma in patients with malignant disease seems to depend only on the extent of the operation. "
|4.||Chronic Hepatitis (Chronic Active Hepatitis)
01/01/1994 - "These findings suggest that serum PIIINP is a relevant marker of activity in patients with viral C chronic hepatitis and that it might have a predictive value of response to treatment."
03/01/1989 - "In our environment, the serum level of P-III-P in the healthy population was 9.12-12.8 ng/ml. In 27.77% of the alcoholics studied (5 cases) the mean value exceeded this level, 19.35 +/- 3.05 ng/ml. Forty percent of the cirrhotics (6 cases) presented the highest values, 26.54 +/- 11.45 ng/ml, while 83.33% of the patients with chronic active hepatitis presented a mean value of 18.53 +/- 3.8 ng/ml. Of the 24 pregnant women, 95.83% (23 cases) had higher than normal values, and concentrations roses in the last trimester of gestation with respect to the previous trimesters. "
12/01/2002 - "114 serum samples from chronic hepatitis patients were assayed for fibrosis indices including HA, PCIII, PIIINP, LN and IV-C with radioimmunoassay (RIA). "
01/01/1994 - "The aim of this study was to evaluate the relationship between the serum N-terminal peptide of type III procollagen (PIIINP), Knodell's score and the response to treatment in 79 patients with viral C chronic hepatitis. "
05/01/1997 - "TGF-beta1 and PIIINP levels in cirrhotic patients were higher than those in patients with chronic hepatitis (each P < .0001) or healthy controls (each P < .0001), respectively. "
05/20/1989 - "In conclusion, P-III-P in sera was very useful as tumor marker in diagnosis of malignant ovarian tumors, while it was not aided to detect the early cancers."
07/01/1995 - "In the junctional area of the stroma around the malignant epithelium, the PIIINP positive fibers grew more sparse and irregular with decreasing differentiation of the tumor. "
09/01/1993 - "The benign tumors were characterized by a regular organization and an intensive staining of PIIINP: Borderline tumors showed a slightly decreased staining intensity and altered PIIINP distribution. "
09/01/1993 - "Another feature typical of malignant tumors was the varying staining intensity of the PIIINP-positive fibers. "
09/01/1993 - "In malignant tumors, the distribution of PIIINP was irregular both close to the epithelial cancer cells and further away, in the stroma. "
|1.||Collagen Type III (Type III Collagen)
|2.||Hyaluronic Acid (Hyaluronan)
|3.||Aligeron (AS 2)
|7.||procollagen type I carboxy terminal peptide (PICP)
|8.||Collagen Type I (Type I Collagen)
|9.||Biological Markers (Surrogate Marker)
|10.||Brain Natriuretic Peptide (Natrecor)
|1.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
|2.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)